Carmustine in Treating Patients With Recurrent Malignant Glioma

Phase 1 Completed National Cancer Institute (NCI)

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carmustine in treating patients who are undergoing surgery for recurrent malignant glioma.

Timeline

Start: 1996-09
Primary completion: —
Completion: —

Publications

Results Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S; New Approaches to Brain Tumor Therapy CNS Consortium. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol. 2003 May 1;21(9):1845-9. doi: 10.1200/JCO.2003.09.041.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	carmustine	Small molecule	6.5 %	Other
Subject	carmustine	Small molecule	10 %	Other
Subject	carmustine	Small molecule	14.5 %	Other
Subject	carmustine	Small molecule	20 %	Other
Subject	carmustine	Small molecule	28 %	Other

Carmustine in Treating Patients With Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications